Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

2036 - Is sentinel lymph node biopsy necessary in breast cancer patients who were diagnosed as initially clinically node-negative before neoadjuvant chemotherapy? (71P)


18 Nov 2017


Poster lunch


Breast Cancer


Takashi Fujita


Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655


T. Fujita, M. Sakuragi, C. Miyazaki, S. Siba, Y. Tanaka, R. Koike, M. Shiozawa

Author affiliations

  • Breast Oncology, Jichi MedicalUniversity Hospital, 329-0498 - Shimotsuke/JP


Abstract 2036


Neoadjuvant chemotherapy (NAC) is established for treatment of locally advanced disease and is being used increasingly for early-stage breast cancer. And sentinel lymph node biopsy (SLNB) for clinically node-negative (cN0) breast cancer patients after NAC is performed as a daily procedure. The purpose of this study was to identify the group that can omit SLNB in patients with cN0 breast cancer at diagnosis before NAC.


A retrospective analysis was performed of 69 patients who were diagnosed as cN0 before NAC and underwent SLNB between 2005 and 2016. Before NAC, all patients underwent clinical assessment of lymph node status by ultrasound. We judged patients to be node-negative when ultrasound showed no suspicious nodes, and if axillar lymph nodes were swelling, fine needle aspiration cytology was performed. 62 patients received anthracycline-based chemotherapy and 6 patients received taxane alone. SLNB procedure and partial resection was done after NAC in all patients. Lymphatic mapping was performed with radioactive colloid and lymphatic blue dye.


Median follow-up time was 48 months. Success rate for the identification and removal of SLNs was 94.2% (65/69). The median number of SLNs removed was 2. In breast cancer patients who were diagnosed as cN0 before NAC, only 5 patients (7.2%) represented SLN involvement and were performed axillar dissection. And the SLNs were the only positive nodes in 3 patients. No SLN metastases were observed in 11 patients who were diagnosed as clinical complete response (cCR) by ultrasound and MRI. But 5 patients (9.3%) had positive SLN in the 54 patients who were diagnosed as clinical partial response or clinical stable disease (p = 0.38). Tumor size, hormone receptor status and HER2 status did not influence the positive rate of SLN metastases. No axillar lymph node recurrence was observed within follow-up period.


Our results show that SLNB is necessary even in breast cancer patients who were diagnosed as cN0 before NAC. But SLNB may be omitted in breast cancer patients who were diagnosed as cN0 before NAC and as cCR by ultrasound and MRI after NAC.

Clinical trial identification

Legal entity responsible for the study

Jichi Medical University




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.